ABM-2752 / ABM Therap - LARVOL DELTA

ABM-2752, a potent and selective HPK1 inhibitor with excellent efficacies as a single agent or in combination with a PD-1 antibody (AACR 2023) - "Preliminary tox studies indicated a good safety window. Based on these preclinical results we plan to file IND in 2023."

Combination therapy • Brain Cancer • CNS Tumor • Glioblastoma • Melanoma • Oncology • Solid Tumor • IL2 • LCP2